A 4-deoxy analogue of N-acetyl-d-glucosamine inhibits heparan sulphate expression and growth factor binding in vitro

Experimental Cell Research

Volumn 316, Issue 15, 2010, Pages 2504-2512

  van Wijk, Xander M R ^a   Oosterhof, Arie ^a   van den Broek, Sebastiaan A M W ^b   Griffioen, Arjan W ^c   ten Dam, Gerdy B ^a   Rutjes, Floris P J T ^b   van Delft, Floris L ^b   van Kuppevelt, Toin H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis; Deoxysugar; Glycosaminoglycan; Growth Factor Binding; Heparan sulfate; N acetyl d glucosamine

Indexed keywords

4 DEOXY GLCNAC; FIBROBLAST GROWTH FACTOR 2; HEPARAN SULFATE; N ACETYLGLUCOSAMINE; UNCLASSIFIED DRUG; VASCULOTROPIN;

AGAR GEL ELECTROPHORESIS; ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MELANOMA; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

EID: 77955049837     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.04.025     Document Type: Article

References (51)

1. Esko J.D., Selleck S.B. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu. Rev. Biochem. 2002, 71:435-471.
2. Dhoot G.K., Gustafsson M.K., Ai X., Sun W., Standiford D.M., Emerson C.P. Regulation of Wnt signaling and embryo patterning by an extracellular sulfatase. Science 2001, 293:1663-1666.
3. Bishop J.R., Schuksz M., Esko J.D. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007, 446:1030-1037.
4. Bernfield M., Gotte M., Park P.W., Reizes O., Fitzgerald M.L., Lincecum J., Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 1999, 68:729-777.
5. Sasisekharan R., Shriver Z., Venkataraman G., Narayanasami U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat. Rev. Cancer 2002, 2:521-528.
6. Yayon A., Klagsbrun M., Esko J.D., Leder P., Ornitz D.M. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991, 64:841-848.
7. Gitay-Goren H., Soker S., Vlodavsky I., Neufeld G. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J. Biol. Chem. 1992, 267:6093-6098.
8. Cohen I.R., Murdoch A.D., Naso M.F., Marchetti D., Berd D., Iozzo R.V. Abnormal expression of perlecan proteoglycan in metastatic melanomas. Cancer Res. 1994, 54:5771-5774.
9. Sharma B., Handler M., Eichstetter I., Whitelock J.M., Nugent M.A., Iozzo R.V. Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J. Clin. Invest. 1998, 102:1599-1608.
10. Alexander C.M., Reichsman F., Hinkes M.T., Lincecum J., Becker K.A., Cumberledge S., Bernfield M. Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat. Genet. 2000, 25:329-332.
11. Khotskaya Y.B., Dai Y., Ritchie J.P., Macleod V., Yang Y., Zinn K., Sanderson R.D. Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo. J. Biol. Chem. 2009, 284:26085-26095.
12. Aikawa T., Whipple C.A., Lopez M.E., Gunn J., Young A., Lander A.D., Korc M. Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells. J. Clin. Invest. 2008, 118:89-99.
13. Narita K., Staub J., Chien J., Meyer K., Bauer M., Friedl A., Ramakrishnan S., Shridhar V. HSulf-1 inhibits angiogenesis and tumorigenesis in vivo. Cancer Res. 2006, 66:6025-6032.
14. Dai Y., Yang Y., MacLeod V., Yue X., Rapraeger A.C., Shriver Z., Venkataraman G., Sasisekharan R., Sanderson R.D. HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo. J. Biol. Chem. 2005, 280:40066-40073.
15. Nawroth R., van Zante A., Cervantes S., McManus M., Hebrok M., Rosen S.D. Extracellular sulfatases, elements of the Wnt signaling pathway, positively regulate growth and tumorigenicity of human pancreatic cancer cells. PLoS ONE 2007, 2:e392.
16. Smetsers T.F., van de Westerlo E.M., ten Dam G.B., Clarijs R., Versteeg E.M., van Geloof W.L., Veerkamp J.H., van Muijen G.N., van Kuppevelt T.H. Localization and characterization of melanoma-associated glycosaminoglycans: differential expression of chondroitin and heparan sulfate epitopes in melanoma. Cancer Res. 2003, 63:2965-2970.
17. ten Dam G.B., van de Westerlo E.M., Purushothaman A., Stan R.V., Bulten J., Sweep F.C., Massuger L.F., Sugahara K., van Kuppevelt T.H. Antibody GD3G7 selected against embryonic glycosaminoglycans defines chondroitin sulfate-E domains highly up-regulated in ovarian cancer and involved in vascular endothelial growth factor binding. Am. J. Pathol. 2007, 171:1324-1333.
18. ten Dam G.B., van de Westerlo E.M., Smetsers T.F., Willemse M., van Muijen G.N., Merry C.L., Gallagher J.T., Kim Y.S., van Kuppevelt T.H. Detection of 2-O-sulfated iduronate and N-acetylglucosamine units in heparan sulfate by an antibody selected against acharan sulfate (IdoA2S-GlcNAc)n. J. Biol. Chem. 2004, 279:38346-38352.
19. Fuster M.M., Esko J.D. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat. Rev. Cancer. 2005, 5:526-542.
20. Liu D., Shriver Z., Venkataraman G., El Shabrawi Y., Sasisekharan R. Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:568-573.
21. Parish C.R., Freeman C., Brown K.J., Francis D.J., Cowden W.B. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res. 1999, 59:3433-3441.
22. Nakajima M., DeChavigny A., Johnson C.E., Hamada J., Stein C.A., Nicolson G.L., Suramin A potent inhibitor of melanoma heparanase and invasion. J. Biol. Chem. 1991, 266:9661-9666.
23. van Kuppevelt T.H., Buiting S., Veerkamp J.H. Feasibility of sequencing glycosaminoglycans using (di)deoxysugar analogues, abstract C16. XVth Meeting of the Federation of European Connective Tissue Societies (FECTS), Munich, Germany 1996.
24. Berkin A., Szarek M.A., Plenkiewicz J., Szarek W.A., Kisilevsky R. Synthesis of 4-deoxy analogues of 2-acetamido-2-deoxy-D-glucose and 2-acetamido-2-deoxy-D-xylose and their effects on glycoconjugate biosynthesis. Carbohydr. Res. 2000, 325:30-45.
25. Kisilevsky R., Szarek W.A., Ancsin J.B., Elimova E., Marone S., Bhat S., Berkin A. Inhibition of amyloid A amyloidogenesis in vivo and in tissue culture by 4-deoxy analogues of peracetylated 2-acetamido-2-deoxy-α- and β-d-glucose: implications for the treatment of various amyloidoses. Am. J. Pathol. 2004, 164:2127-2137.
26. Berkin A., Szarek W.A., Kisilevsky R. Biological evaluation of a series of 2-acetamido-2-deoxy-d-glucose analogs towards cellular glycosaminoglycan and protein synthesis in vitro. Glycoconj. J. 2005, 22:443-451.
27. Hull R.L., Zraika S., Udayasankar J., Kisilevsky R., Szarek W.A., Wight T.N., Kahn S.E. Inhibition of glycosaminoglycan synthesis and protein glycosylation with WAS-406 and azaserine result in reduced islet amyloid formation in vitro. Am. J. Physiol. Cell Physiol. 2007, 293:C1586-1593.
28. Kisilevsky R., Ancsin J.B., Szarek W.A., Petanceska S. Heparan sulfate as a therapeutic target in amyloidogenesis: prospects and possible complications. Amyloid 2007, 14:21-32.
29. Sutherlin D.P., Stark T.M., Hughes R., Armstrong R.W. Generation of C-glycoside peptide ligands for cell surface carbohydrate receptors using a four-component condensation on solid support. J. Org. Chem. 1996, 61:8350-8354.
30. Barton D.H.R., McCombie S.W. A new method for the deoxygenation of secondary alcohols. J. Chem. Soc. Perkin Trans. 1975, 1:1574-1585.
31. van Muijen G.N., Jansen K.F., Cornelissen I.M., Smeets D.F., Beck J.L., Ruiter D.J. Establishment and characterization of a human melanoma cell line (MV3) which is highly metastatic in nude mice. Int. J. Cancer 1991, 48:85-91.
32. Jenniskens G.J., Oosterhof A., Brandwijk R., Veerkamp J.H., van Kuppevelt T.H. Heparan sulfate heterogeneity in skeletal muscle basal lamina: demonstration by phage display-derived antibodies. J. Neurosci. 2000, 20:4099-4111.
33. van Kuppevelt T.H., Dennissen M.A., van Venrooij W.J., Hoet R.M., Veerkamp J.H. Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology. Further evidence for heparan sulfate heterogeneity in the kidney. J. Biol. Chem. 1998, 273:12960-12966.
34. Nillesen S.T., Geutjes P.J., Wismans R., Schalkwijk J., Daamen W.F., van Kuppevelt T.H. Increased angiogenesis and blood vessel maturation in acellular collagen-heparin scaffolds containing both FGF2 and VEGF. Biomaterials 2007, 28:1123-1131.
35. van de Lest C.H., Versteeg E.M., Veerkamp J.H., van Kuppevelt T.H. Quantification and characterization of glycosaminoglycans at the nanogram level by a combined azure A-silver staining in agarose gels. Anal. Biochem. 1994, 221:356-361.
36. Dings R.P., van der Schaft D.W., Hargittai B., Haseman J., Griffioen A.W., Mayo K.H. Anti-tumor activity of the novel angiogenesis inhibitor anginex. Cancer Lett. 2003, 194:55-66.
37. Griffioen A.W., Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev. 2000, 52:237-268.
38. Lewis K.D., Robinson W.A., Millward M.J., Powell A., Price T.J., Thomson D.B., Walpole E.T., Haydon A.M., Creese B.R., Roberts K.L., Zalcberg J.R., Gonzalez R. A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest. New Drugs 2008, 26:89-94.
39. Lin X., Wei G., Shi Z., Dryer L., Esko J.D., Wells D.E., Matzuk M.M. Disruption of gastrulation and heparan sulfate biosynthesis in EXT1-deficient mice. Dev. Biol. 2000, 224:299-311.
40. Stickens D., Zak B.M., Rougier N., Esko J.D., Werb Z. Mice deficient in Ext2 lack heparan sulfate and develop exostoses. Development 2005, 132:5055-5068.
41. Fuster M.M., Wang L., Castagnola J., Sikora L., Reddi K., Lee P.H., Radek K.A., Schuksz M., Bishop J.R., Gallo R.L., Sriramarao P., Esko J.D. Genetic alteration of endothelial heparan sulfate selectively inhibits tumor angiogenesis. J. Cell Biol. 2007, 177:539-549.
42. Habuchi H., Nagai N., Sugaya N., Atsumi F., Stevens R.L., Kimata K. Mice deficient in heparan sulfate 6-O-sulfotransferase-1 exhibit defective heparan sulfate biosynthesis, abnormal placentation, and late embryonic lethality. J. Biol. Chem. 2007, 282:15578-15588.
43. Nigro J., Wang A., Mukhopadhyay D., Lauer M., Midura R.J., Sackstein R., Hascall V.C. Regulation of heparan sulfate and chondroitin sulfate glycosaminoglycan biosynthesis by 4-fluoro-glucosamine in murine airway smooth muscle cells. J. Biol. Chem. 2009, 284:16832-16839.
44. Kan M., Wang F., Xu J., Crabb J.W., Hou J., McKeehan W.L. An essential heparin-binding domain in the fibroblast growth factor receptor kinase. Science 1993, 259:1918-1921.
45. Lundin L., Larsson H., Kreuger J., Kanda S., Lindahl U., Salmivirta M., Claesson-Welsh L. Selectively desulfated heparin inhibits fibroblast growth factor-induced mitogenicity and angiogenesis. J. Biol. Chem. 2000, 275:24653-24660.
46. Jakobsson L., Kreuger J., Holmborn K., Lundin L., Eriksson I., Kjellen L., Claesson-Welsh L. Heparan sulfate in trans potentiates VEGFR-mediated angiogenesis. Dev. Cell 2006, 10:625-634.
47. Sasisekharan R., Moses M.A., Nugent M.A., Cooney C.L., Langer R. Heparinase inhibits neovascularization. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:1524-1528.
48. Maccarana M., Casu B., Lindahl U. Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. J. Biol. Chem. 1993, 268:23898-23905.
49. Robinson C.J., Mulloy B., Gallagher J.T., Stringer S.E. VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase. J. Biol. Chem. 2006, 281:1731-1740.
50. Varki A., Cummings R.D., Esko J.D., Freeze H.H., Stanley P., Bertozzi C.R., Hart G.W., Etzler M.E. Antibodies and lectins in glycan analysis, essentials of glycobiology 2009, Cold Spring Harbor Laboratory Press, New York, USA, pp. 633-647.
51. Tian E., Ten Hagen K.G. O-linked glycan expression during Drosophila development. Glycobiology 2007, 17:820-827.